Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Talon May Soon Have First Marqibo Approval In Its Grasp

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.

You may also be interested in...



Talon Marqibo’s Fate May Hang On Adjudication Of Trial Subjects

With Talon offering a single Phase II trial to support its NDA for Marqibo (vincristine sulfate liposomal injection) for relapsed Philadelphia chromosome negative acute lymphoblastic leukemia, everything may hinge on the disagreement between the sponsor and FDA over whether eight patients or 13 out of 65 experienced some type of complete response.

Hana Passes Zensana Development To Par

Deal valued at up to $50 million will allow Hana to proceed with development of oncology candidates, Hana said.

No Simple Fix For Precipitate Problem; Hana Withdraws Zensana NDA

Hana also drops its SPA request for Marqibo, citing a change in FDA policy on open-label oncology trials.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel